Bayer pondering Boots OTC buy?
This article was originally published in The Rose Sheet
Executive Summary
German drugmaker may consider acquiring Boots Healthcare International, Bayer CEO Werner Wenning says during Aug. 10 earnings call. "We never comment on a specific transaction...[but] we are always looking in all our areas behind directive targets to increase our position in specific markets," exec states, adding "the consumer care market is an attractive market and an important market for us, and if [BHI] is available in reasonable terms, of course we are interested." Boots the Chemists announced plans to divest its consumer health care business this spring (1"The Rose Sheet" April 11, 2005, p. 9). GlaxoSmithKline also has been mentioned as a potential buyer...
You may also be interested in...
Boots To Unload OTC Business, Citing Market Consolidation
Merger and acquisition activity in the OTC drug industry has prompted Boots the Chemists to put its healthcare unit up for sale
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.